Show simple item record

dc.contributor.authorMohanan, Sunish
dc.contributor.authorCherrington, Brian D.
dc.contributor.authorHoribata, Sachi
dc.contributor.authorMcElwee, John L.
dc.contributor.authorThompson, Paul R
dc.contributor.authorCoonrod, Scott A.
dc.date2022-08-11T08:11:00.000
dc.date.accessioned2022-08-23T17:28:13Z
dc.date.available2022-08-23T17:28:13Z
dc.date.issued2012-09-29
dc.date.submitted2015-05-22
dc.identifier.citationBiochem Res Int. 2012;2012:895343. Epub 2012 Sep 16. <a href="http://dx.doi.org/10.1155/2012/895343">Link to article on publisher's site</a>
dc.identifier.issn2090-2255 (Electronic)
dc.identifier.doi10.1155/2012/895343
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50032
dc.description<p>At the time of publication, Paul Thompson was not yet affiliated with UMass Medical School.</p>
dc.description.abstractThe peptidylarginine deiminases (PADs) are a family of posttranslational modification enzymes that catalyze the conversion of positively charged protein-bound arginine and methylarginine residues to the uncharged, nonstandard amino acid citrulline. This enzymatic activity is referred to as citrullination or, alternatively, deimination. Citrullination can significantly affect biochemical pathways by altering the structure and function of target proteins. Five mammalian PAD family members (PADs 1-4 and 6) have been described and show tissue-specific distribution. Recent reviews on PADs have focused on their role in autoimmune diseases. Here, we will discuss the potential role of PADs in tumor progression and tumor-associated inflammation. In the context of cancer, increasing clinical evidence suggests that PAD4 (and possibly PAD2) has important roles in tumor progression. The link between PADs and cancer is strengthened by recent findings showing that treatment of cell lines and mice with PAD inhibitors significantly suppresses tumor growth and, interestingly, inflammatory symptoms. At the molecular level, transcription factors, coregulators, and histones are functional targets for citrullination by PADs, and citrullination of these targets can affect gene expression in multiple tumor cell lines. Next generation isozyme-specific PAD inhibitors may have therapeutic potential to regulate both the inflammatory tumor microenvironment and tumor cell growth.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23019525&dopt=Abstract">Link to Article in PubMed</a>
dc.rightsCopyright © 2012 Sunish Mohanan et al. This is an open access article distributed under the <a href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/
dc.subjectBiochemistry
dc.subjectEnzymes and Coenzymes
dc.subjectMedicinal-Pharmaceutical Chemistry
dc.subjectTherapeutics
dc.titlePotential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis.
dc.typeJournal Article
dc.source.journaltitleBiochemistry research international
dc.source.volume2012
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1040&amp;context=thompson&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/thompson/41
dc.identifier.contextkey7135708
refterms.dateFOA2022-08-23T17:28:13Z
html.description.abstract<p>The peptidylarginine deiminases (PADs) are a family of posttranslational modification enzymes that catalyze the conversion of positively charged protein-bound arginine and methylarginine residues to the uncharged, nonstandard amino acid citrulline. This enzymatic activity is referred to as citrullination or, alternatively, deimination. Citrullination can significantly affect biochemical pathways by altering the structure and function of target proteins. Five mammalian PAD family members (PADs 1-4 and 6) have been described and show tissue-specific distribution. Recent reviews on PADs have focused on their role in autoimmune diseases. Here, we will discuss the potential role of PADs in tumor progression and tumor-associated inflammation. In the context of cancer, increasing clinical evidence suggests that PAD4 (and possibly PAD2) has important roles in tumor progression. The link between PADs and cancer is strengthened by recent findings showing that treatment of cell lines and mice with PAD inhibitors significantly suppresses tumor growth and, interestingly, inflammatory symptoms. At the molecular level, transcription factors, coregulators, and histones are functional targets for citrullination by PADs, and citrullination of these targets can affect gene expression in multiple tumor cell lines. Next generation isozyme-specific PAD inhibitors may have therapeutic potential to regulate both the inflammatory tumor microenvironment and tumor cell growth.</p>
dc.identifier.submissionpaththompson/41
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages895343


Files in this item

Thumbnail
Name:
895343.pdf
Size:
6.791Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2012 Sunish Mohanan et al. This is an open access article distributed under the <a href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright © 2012 Sunish Mohanan et al. This is an open access article distributed under the <a href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.